Abstract
BACKGROUND Brain age, a proxy of overall brain health estimated from structural neuroimaging, has been associated with sensorimotor performance in chronic stroke. Similarly, post-stroke cognitive outcomes have been associated with accelerated brain aging. However, the relationships between brain age, sensorimotor, and cognitive outcomes in early subacute stroke (<3 months after onset) are less understood.
METHODS In this work, we investigated associations between stroke survivors’ brain-predicted age difference (brain-PAD, quantified as a person’s brain age minus their chronological age) and longitudinal measurements of motor impairment (Fugl-Meyer Upper Extremity Assessment [FMUE]) and cognitive impairment (Montreal Cognitive Assessment [MoCA]) in subacute stroke. We used high-resolution T1-weighted MRIs from 44 participants at baseline and three months after stroke onset to investigate associations between brain-PAD, MoCA, and FMUE scores with robust linear mixed-effects regression models and mediation analyses.
RESULTS We found negative associations between baseline brain-PAD and FMUE at baseline (β=-0.87, p=0.029) and three months (β=-0.87, p=0.011). Baseline brain-PAD was also negatively correlated with MoCA at three months (β=-0.13, p=0.015) but not at baseline (β=-0.11, p=0.141). Baseline brain-PAD was not associated with changes in FMUE (β=-0.01, p=0.930) or MoCA (β=-0.03, p=0.579). Finally, MoCA was not associated with FMUE at either time point, nor did it mediate the relationship between brain-PAD and FMUE.
CONCLUSION Overall, we show that baseline brain age predicts both motor and cognitive outcomes at three months. However, motor and cognitive outcomes are not directly associated with one other. This suggests that brain age is representative of changes in multiple, distinct neurological pathways post-stroke. Further research with longer time intervals is needed to examine whether brain age also predicts chronic stroke outcomes.
Competing Interest Statement
J.H.C is a shareholder and scientific advisor to Brain Key and Claritas HealthTech. S.C.C. is a consultant for Constant Therapeutics, BrainQ, Myomo, MicroTransponder, Panaxium, Beren Therapeutics, Medtronic, NeuroTrauma Sciences, BlueRock Therapeutics, Simcere, and TRCare. S.-L.L. is a consultant for Synchron and co-owner of Ardist Inc. All other authors report no competing interests.
Funding Statement
Research reported in this publication was supported by the Office Of The Director, National Institutes Of Health of the National Institutes of Health under Award Number S10 OD032285, as well as R01 NS115845. Additional support was provided by NIH NINDS R56 NS126748 and NIH R01 NS110696.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki. The University of Southern California Health Sciences Campus Institutional Review Board and the local ethics board of each cohort (Casa Colina Hospital, Emory University, and NYU Langone Health) approved to conduct this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos